EVO301
Atopic Dermatitis
Key Facts
About Evommune
Evommune is a clinical-stage biotech developing oral therapies targeting mast cells and sensory neurons to address the root causes of chronic inflammatory diseases like atopic dermatitis and chronic spontaneous urticaria. The company has advanced two lead programs, EVO756 and EVO301, into Phase 2 trials, supported by a recent $125 million private placement. Its strategy focuses on achieving disease-modifying effects with convenient oral dosing, aiming to capture significant share in multi-billion dollar immunology markets with high unmet need.
View full company profileAbout Evommune
Evommune is a clinical-stage biotech developing oral therapies targeting mast cells and sensory neurons to address the root causes of chronic inflammatory diseases like atopic dermatitis and chronic spontaneous urticaria. The company has advanced two lead programs, EVO756 and EVO301, into Phase 2 trials, supported by a recent $125 million private placement. Its strategy focuses on achieving disease-modifying effects with convenient oral dosing, aiming to capture significant share in multi-billion dollar immunology markets with high unmet need.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| Encube-003 | Encube Ethicals | Preclinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| MEndoB | Micreos | Pre-clinical |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| B244 | AOBiome | Phase 3 |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |